NCT02625246 (CELEB) is a Phase 1 clinical trial of hMSCs in Bronchiectasis, sponsored by Marilyn Glassberg.

Who is sponsoring NCT02625246?

NCT02625246 is sponsored by Marilyn Glassberg.

What drugs are being tested in NCT02625246?

Interventions in NCT02625246: hMSCs.

What condition does NCT02625246 study?

NCT02625246 studies Bronchiectasis.

Is NCT02625246 still recruiting?

NCT02625246 is currently completed. Last updated 28 August 2019.

Last reviewed 2019-08-28 · How we verify

NCT02625246: CELEB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis

Completed Phase 1 Last updated 28 August 2019

What this trial tests

Phase 1 trial testing hMSCs in Bronchiectasis in 6 participants. Completed in 15 May 2019.

Timeline

4 February 2016

Primary endpoint
15 May 2019

15 May 2019

Quick facts

Lead sponsor	Marilyn Glassberg
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	4 February 2016
Primary completion	15 May 2019
Estimated completion	15 May 2019
Sites	1 location across United States

Drugs / interventions tested

hMSCs — full drug profile →

Conditions studied

Bronchiectasis — all drugs for Bronchiectasis →

Sponsor

Marilyn Glassberg — full company profile →

Who can join

Adults 30 to 87, any sex, with Bronchiectasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To demonstrate the safety of bone marrow-derived allogeneic human Mesenchymal Stem Cells (hMSCs) in patients with bronchiectasis receiving standard of care therapy, and to explore treatment efficacy

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin.
Qin L, Liu N, Bao CL, Yang DZ, et al · · 2023 · cited 74× · PMID 35896695 · DOI 10.1038/s41401-022-00952-0
Mesenchymal stem cells in the pathogenesis and treatment of bronchopulmonary dysplasia: a clinical review.
Simones AA, Beisang DJ, Panoskaltsis-Mortari A, Roberts KD. · · 2018 · cited 32× · PMID 28945702 · DOI 10.1038/pr.2017.237
The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782
Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases.
Shaw TD, Krasnodembskaya AD, Schroeder GN, Zumla A, et al · · 2021 · cited 27× · PMID 34612662 · DOI 10.1128/cmr.00064-21
Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review.
Chen X, Wang F, Huang Z, Wu Y, et al · · 2021 · cited 23× · PMID 34220313 · DOI 10.7150/ijms.59218

Verify or expand the search:

Other trials of hMSCs

Trials testing the same drug.

NCT03137199 — Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma · Phase 1 · terminated

Other recruiting trials for Bronchiectasis

Currently open trials in the same condition.

NCT07283497 — Itraconazole Therapy In Bronchiectasis With Airway Mold · Phase 4 · recruiting
NCT07188675 — Functional Inspiratory Training in Bronchiectasis · NA · recruiting
NCT06897761 — Development of an Interactive Digital Respiratory Game and Device and Investigation of Its Effectiveness in Children Wit · NA · recruiting
NCT07147803 — Sleep Quality in Patients With Non-cystic Fibrosis Bronchiectasis · active not recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting

Other Marilyn Glassberg trials

Trials by the same sponsor.

NCT03137199 — Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02625246 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Marilyn Glassberg
Last refreshed: 28 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02625246.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing